SCHEMBL30765733

SCHEMBL30765733

Cc1cn(CC(=O)OC(C)(C)C)c(=O)c(N[C@H](C)c2ccc3oc4ccccc4c3c2)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.36
RXFP1 Q9HBX9 3/20 0.34
NPSR1 Q6W5P4 1/20 0.34
LMNA P02545 6/20 0.34
KDM4E B2RXH2 4/20 0.34
TSHR P16473 2/20 0.34
HTT P42858 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
TP53 P04637 1/20 0.34
ALOX15 P16050 1/20 0.34
POLB P06746 1/20 0.34
ALDH1A1 P00352 2/20 0.33
HDAC6 Q9UBN7 1/20 0.33
SOS1 Q07889 2/20 0.33
HPGD P15428 2/20 0.33
ELANE P08246 1/20 0.33
CTRB1 P17538 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765962 0.91 KMT2A (0.35) KMT2ARXFP1NPSR1LMNAKDM4E
SCHEMBL30765676 0.88 SOS1 (0.41) KMT2ARXFP1LMNAKDM4ETSHR
SCHEMBL30765920 0.86 L3MBTL1 (0.41) KMT2ARXFP1NPSR1LMNAKDM4E
SCHEMBL30765521 0.86 KMT2A (0.38) KMT2ARXFP1NPSR1LMNAKDM4E
SCHEMBL30765797 0.81 KMT2A (0.40) KMT2ARXFP1NPSR1LMNAKDM4E
SCHEMBL30765729 0.79 ALDH1A1 (0.38) KMT2ARXFP1NPSR1LMNAKDM4E
SCHEMBL30765893 0.79 ALDH1A1 (0.33) KMT2ARXFP1NPSR1LMNAKDM4E
SCHEMBL30765712 0.78 LMNA (0.35) NPSR1LMNAKDM4ETSHRHTT
SCHEMBL30765468 0.78 LMNA (0.40) KMT2ARXFP1NPSR1LMNAKDM4E
SCHEMBL30765991 0.77 ELANE (0.42) LMNAKDM4EALDH1A1ELANECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed